Nitto Boseki Co., Ltd. engages in the manufacture processing and sale of textile products and materials. It operates through the following business segments: Textiles, Raw Fiber Materials, Functional Materials, Equipment Materials, Life Science, and Others. The Textiles segment handles the manufacture and sale of core spun yarn, stretch products, interlining products and others. The Raw Fiber Materials segment manufactures and sells fiberglass raw fiber products like yarn, roving, and chopped strands. The Functional Materials segment covers the manufacture and sales of glass fiber functional products. The Equipment Materials segment includes glass fiber products for industrial materials, and manufactures and sells glass wool products (for heat insulating materials). The Life Science segment manufactures and sells in-vitro diagnostic drugs, specialty chemicals products, and soft drinks. The Others segment deals with industrial machinery and equipment related business and service business. The company was founded on April 18, 1918 and is headquartered in Tokyo, Japan.

Nycomed is a privately owned global pharmaceutical company with a diversified portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. A range of OTC products completes the portfolio. Its R&D is structured around collaborations. In-licensing and expanding in emerging markets are cornerstones of the company's growth strategy. Nycomed employs 12,500 associates worldwide, and its products are sold in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, Latin America, Asia and the Middle East. In the US and Japan its products are available through best in class partners. Headquartered in Zurich, Switzerland, the company generated total sales of € 3.2 billion in 2010 and an adjusted EBITDA of € 851 million.

Provides bio-pharmaceutical research development services

Behringwerke AG, a subsidiary of Sanofi, is a German company located in Marburg. The firm produces specialty chemicals and pharmaceutical products.

LSI Medience Corp. engages in the clinical examination business. It also engages in the diagnostic agent and drug discovery support business. The company was founded on April 1, 2014 and is headquartered in Tokyo, Japan.

Laboratoire Francais du Fractionnement et des Biotechnologies SA provides plasma-derived medicinal products. It undertakes research and development programs in plasma fractions and biotechnologies in the areas of autoimmune diseases and hemostasis disorders. The firm's products include albumin and immunoglobulin. It also offers products for rare pathologies. The company was founded in 1994 and is headquartered in Les Ulis, France.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Topaz Investment AS is a private company headquartered in Norway that provides investment services.

Hualan Biological Engineering is a key National high-tech biopharmaceutical company in China engaging in the research, development, production, and commercialization of plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics. The plasma products offered by the company include Human albumin, Human fibrinogen, Human tetanus immunoglobulin and others. The vaccines products include Recombinant hepatitis B vaccine, Inactivated influenza vaccine and other. It also offers gene products such as Monoclonal Antibody for tumor, autoimmune diseases, infectious diseases, transplant rejection, and Recombinant monoclonal antibodies.

Servier are driven by the belief in the excellence of their profession. Theirs is a research-based organization, fulfilling a basic need and dedicated to the future.

Beijing Anxin Huaide Biotechnology Co., Ltd., established on 2012-04-18, Business scope includes biological products(human stem cells,Except for the development and application of genetic diagnosis and treatment technology),Pharmaceutical technology development,technical consulting,technology transfer,Technical Services.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Kangchen Pharmaceutical Co. Ltd. is a Chinese private company located in Beijing that manufactures medical devices.

Beijing Konruns Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of new drugs, with a focus on new special drugs. The company was founded by Xi Juan Wang and Jian Hua Liu on September 3, 2003 and is headquartered in Beijing, China.

China Resources Boya Bio-pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of blood products. It operates through the following business segments: Blood Products, Diabetes Medication, and Biochemical drugs. The Blood Products segment includes products such as albumin, immunoglobulin, and blood clotting factors. The Diabetes Medication segment includes metformin hydrochloride tablets, enteric-coated tablets, and calcium hydroxybenzenesulfonate capsules. The Biochemical Drugs segment includes medication such as compound bone peptide injections, oxytocin injections, and heparin sodium injections. The company was founded on November 6, 1993 and is headquartered in Fuzhou, China.

Biobud Ltd. engages in the development of biopharmaceuticals for cardiovascular prevention, diagnosis and treatment. The company was founded on March 28, 2000, and is headquartered in Seongnam, South Korea.

Chengdu Rongsheng Pharmaceutical Co., Ltd. operates as a plasma-processing company in China. It produces plasma derivatives, such as albumin and intravenous immunoglobulin, and hepatitis B and tetanus immunoglobulins. The company was founded in 1997 and is based in Chengdu, China. Chengdu Rongsheng Pharmaceutical Co., Ltd. operates as a former subsidiary of Chengdu Institute Of Biological Products. As per the transaction announced on June 24, 2008, Chengdu Rongsheng Pharmaceutical Co., Ltd. operates as a subsidiary of Beijing Tiantan Biological Products Co., Ltd..